Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 30, 2008, Pages 10360-10365

  Boeckler, Frank M ^a,b   Joerger, Andreas C ^a   Jaggi, Gaurav ^a   Rutherford, Trevor J ^a   Veprintsev, Dmitry B ^a   Fersht, Alan R ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Crystal structure; NMR screen; Oncogenic mutant; Protein stabilization; Virtual drug design

Indexed keywords

CARBAZOLE DERIVATIVE; PROTEIN P53;

ARTICLE; COMPUTER MODEL; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG SCREENING; GENE MUTATION; HIGH THROUGHPUT SCREENING; NITROGEN NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTON NUCLEAR MAGNETIC RESONANCE; THERMOSTABILITY;

APOPTOSIS; BIOPHYSICS; CALORIMETRY; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DNA MUTATIONAL ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR CONFORMATION; MUTATION; NEOPLASMS; THERMODYNAMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48749103325     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805326105     Document Type: Article

References (43)

1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310.
2. Vousden KH, Lu X (2002) Live or let die: The cell's response to p53. Nat Rev Cancer 2:594-604.
3. Joerger AC, Fersht AR (2008) Structural Biology of the tumor suppressor p53. Annu Rev Biochem 77:557-582.
4. Olivier M, et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19:607-614.
5. Joerger AC, Fersht AR (2007) Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26:2226-2242.
6. Bullock AN, et al. (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA 94:14338-14342.
7. Ang HC, Joerger AC, Mayer S, Fersht AR (2006) Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem 281:21934-21941.
8. Friedler A, Veprintsev DB, Hansson LO, Fersht AR (2003) Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem 278:24108-24112.
9. Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene 19:1245-1256.
10. Rippin TM, et al. (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119-2129.
11. Friedler A, et al. (2002) A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99:937-942.
12. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510.
13. Issaeva N, et al. (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100:13303-13307.
14. Tanner S, Barberis A (2004) CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed 3:5.
15. Tang X, et al. (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117:3753-3764.
16. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103:15056-15061.
17. Petitjean A, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629.
18. Nikolova PV, Henckel J, Lane DP, Fersht AR (1998) Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci USA 95:14675-14680.
19. Joerger AC, Allen MD, Fersht AR (2004) Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 279:1291-1296.
20. Irwin JJ, Shoichet BK (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182.
21. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
22. Chemical Computing Group (2005) MOE (Chemical Computing Group Inc, Montreal, Canada), Ver. 2005.06.
23. Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 245:43-53.
24. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748.
25. Weinberg RL, Veprintsev DB, Fersht AR (2004) Cooperative binding of tetrameric p53 to DNA. J Mol Biol 341:1145-1159.
26. Velec HFG, Gohlke H, Klebe G (2005) DrugScoreCSD-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. J Med Chem 48:6296-6303.
27. Fastrez J, Fersht AR (1973) Mechanism of chymotrypsin, structure, reactivity, and nonproductive binding relationships. Biochemistry 12:1067-1074.
28. Lenz C, Boeckler F, Hubner H, Gmeiner P (2004) Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists. Bioorg Med Chem 12:113-117.
29. Lenz C, Haubmann C, Hubner H, Boeckler F, Gmeiner P (2005) Fancy bioisosteres: Synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel nonaromatic D3 agonist. Bioorg Med Chem 13:185-191.
30. Lenz C, Boeckler F, Hubner H, Gmeiner P (2005) Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands. Bioorg Med Chem 13:4434-4442.
31. Boeckler F, Lanig H, Gmeiner P (2005) Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. J Med Chem 48:694-709.
32. Boeckler F, et al. (2005) CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists. J Med Chem 48:2493-2508.
33. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR (2005) Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 280:16030-16037.
34. Canadillas JM, et al. (2006) Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci USA 103:2109-2114.
35. Tidow H, Andreeva A, Rutherford TJ, Fersht AR (2007) Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a ubiquitin-like fold. J Mol Biol 371:948-958.
36. Goddard TD, Kneller DG (2006) SPARKY 3 (University of California, San Francisco).
37. Mayer S, Rudiger S, Ang HC, Joerger AC, Fersht AR (2007) Correlation of levels of folded recombinant p53 in Escherichia coli with thermodynamic stability in vitro. J Mol Biol 372:268-276.
38. Leslie AGW (1992) Recent Changes to the MOSFLM package for processing film and image plate data. Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography (Daresbury Laboratory, Warrington, UK), Vol. 26.
39. Collaborative Computational Project N (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D 50:760-763.
40. Brünger AT, et al. (1998) Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D 54: 905-921.
41. Turk D (1992) PhD thesis (Technische Universität München, Munich, Germany).
42. Kitayner M, et al. (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741-753.
43. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.